Literature DB >> 1996098

Episome-generated N-myc antisense RNA restricts the differentiation potential of primitive neuroectodermal cell lines.

L Whitesell1, A Rosolen, L M Neckers.   

Abstract

Neuroectodermal tumors of childhood provide a unique opportunity to examine the role of genes potentially regulating neuronal growth and differentiation because many cell lines derived from these tumors are composed of at least two distinct morphologic cell types. These types display variant phenotypic characteristics and spontaneously interconvert, or transdifferentiate, in vitro. The factors that regulate transdifferentiation are unknown. Application of antisense approaches to the transdifferentiation process has allowed us to explore the precise role that N-myc may play in regulating developing systems. We now report construction of an episomally replicating expression vector designed to generate RNA antisense to part of the human N-myc gene. Such a vector is able to specifically inhibit N-myc expression in cell lines carrying both normal and amplified N-myc alleles. Inhibition of N-myc expression blocks transdifferentiation in these lines, with accumulation of cells of an intermediate phenotype. A concomitant decrease in growth rate but not loss of tumorigenicity was observed in the N-myc nonamplified cell line CHP-100. Vector-generated antisense RNA should allow identification of genes specifically regulated by the proto-oncogene N-myc.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1996098      PMCID: PMC369407          DOI: 10.1128/mcb.11.3.1360-1371.1991

Source DB:  PubMed          Journal:  Mol Cell Biol        ISSN: 0270-7306            Impact factor:   4.272


  31 in total

1.  Antisense inhibition of single copy N-myc expression results in decreased cell growth without reduction of c-myc protein in a neuroepithelioma cell line.

Authors:  A Rosolen; L Whitesell; N Ikegaki; R H Kennett; L M Neckers
Journal:  Cancer Res       Date:  1990-10-01       Impact factor: 12.701

2.  N-myc can cooperate with ras to transform normal cells in culture.

Authors:  G D Yancopoulos; P D Nisen; A Tesfaye; N E Kohl; M P Goldfarb; F W Alt
Journal:  Proc Natl Acad Sci U S A       Date:  1985-08       Impact factor: 11.205

3.  Definition of a continuous human cell line derived from neuroblastoma.

Authors:  J J Tumilowicz; W W Nichols; J J Cholon; A E Greene
Journal:  Cancer Res       Date:  1970-08       Impact factor: 12.701

4.  Stable replication of plasmids derived from Epstein-Barr virus in various mammalian cells.

Authors:  J L Yates; N Warren; B Sugden
Journal:  Nature       Date:  1985 Feb 28-Mar 6       Impact factor: 49.962

5.  Expression and amplification of the N-myc gene in primary retinoblastoma.

Authors:  W H Lee; A L Murphree; W F Benedict
Journal:  Nature       Date:  1984 May 31-Jun 6       Impact factor: 49.962

6.  Retinoic acid induces neuronal differentiation of a cloned human embryonal carcinoma cell line in vitro.

Authors:  P W Andrews
Journal:  Dev Biol       Date:  1984-06       Impact factor: 3.582

7.  Amplified DNA with limited homology to myc cellular oncogene is shared by human neuroblastoma cell lines and a neuroblastoma tumour.

Authors:  M Schwab; K Alitalo; K H Klempnauer; H E Varmus; J M Bishop; F Gilbert; G Brodeur; M Goldstein; J Trent
Journal:  Nature       Date:  1983 Sep 15-21       Impact factor: 49.962

8.  Decreased expression of N-myc precedes retinoic acid-induced morphological differentiation of human neuroblastoma.

Authors:  C J Thiele; C P Reynolds; M A Israel
Journal:  Nature       Date:  1985 Jan 31-Feb 6       Impact factor: 49.962

9.  Transposition and amplification of oncogene-related sequences in human neuroblastomas.

Authors:  N E Kohl; N Kanda; R R Schreck; G Bruns; S A Latt; F Gilbert; F W Alt
Journal:  Cell       Date:  1983-12       Impact factor: 41.582

10.  Coordinate morphological and biochemical interconversion of human neuroblastoma cells.

Authors:  R A Ross; B A Spengler; J L Biedler
Journal:  J Natl Cancer Inst       Date:  1983-10       Impact factor: 13.506

View more
  8 in total

1.  Loss of tumorigenicity of rat glioblastoma directed by episome-based antisense cDNA transcription of insulin-like growth factor I.

Authors:  J Trojan; B K Blossey; T R Johnson; S D Rudin; M Tykocinski; J Ilan; J Ilan
Journal:  Proc Natl Acad Sci U S A       Date:  1992-06-01       Impact factor: 11.205

2.  The use of Epstein-Barr virus-based shuttle vectors in rat PC12 cells.

Authors:  L Lindenboim; D Anderson; R Stein
Journal:  Cell Mol Neurobiol       Date:  1997-02       Impact factor: 5.046

3.  Characteristics of stem cells from human neuroblastoma cell lines and in tumors.

Authors:  Jeanette D Walton; David R Kattan; Sharon K Thomas; Barbara A Spengler; Hong-Fen Guo; June L Biedler; Nai-Kong V Cheung; Robert A Ross
Journal:  Neoplasia       Date:  2004 Nov-Dec       Impact factor: 5.715

4.  MYCN silencing induces differentiation and apoptosis in human neuroblastoma cells.

Authors:  Jung-Hee Kang; Piotr G Rychahou; Titilope A Ishola; Jingbo Qiao; B Mark Evers; Dai H Chung
Journal:  Biochem Biophys Res Commun       Date:  2006-10-12       Impact factor: 3.575

5.  Gene-targeted inhibition of transactivation of human immunodeficiency virus type-1 (HIV-1)-LTR by antisense oligonucleotides.

Authors:  I Demirhan; O Hasselmayer; D Hofmann; A Chandra; F P Svinarchuk; V V Vlassov; J Engels; P Chandra
Journal:  Virus Genes       Date:  1995-01       Impact factor: 2.332

6.  RB2/p130 ectopic gene expression in neuroblastoma stem cells: evidence of cell-fate restriction and induction of differentiation.

Authors:  F P Jori; U Galderisi; E Piegari; G Peluso; M Cipollaro; A Cascino; A Giordano; M A Melone
Journal:  Biochem J       Date:  2001-12-15       Impact factor: 3.857

Review 7.  Biology of pediatric peripheral neuroectodermal tumors.

Authors:  C J Thiele
Journal:  Cancer Metastasis Rev       Date:  1991-12       Impact factor: 9.264

Review 8.  MYCN, neuroblastoma and focal adhesion kinase (FAK).

Authors:  Elizabeth A Beierle
Journal:  Front Biosci (Elite Ed)       Date:  2011-01-01
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.